CoChat

The DOI matches its Crossref record; 54 of the 61 references it cites were found in a registry or an index; 27 of the 36 sources its claims cite were checked for support.

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer

Open access

Abstract

Abstract Colorectal cancer (CRC), which shows a high degree of heterogeneity, is the third most deadly cancer worldwide. Mutational activation of KRAS G12D occurs in approximately 10–12% of CRC cases, but the susceptibility of KRAS G12D -mutated CRC to the recently discovered KRAS G12D inhibitor MRTX1133 has not been fully defined. Here, we report that MRTX1133 treatment caused reversible growth arrest in KRAS G12D -mutated CRC cells, accompanied by partial reactivation of RAS effector signaling. Through a drug-anchored synthetic lethality screen, we discovered that epidermal growth factor receptor (EGFR) inhibition was synthetic lethal with MRTX1133. Mechanistically, MRTX1133 treatment downregulated the expression of ERBB receptor feedback inhibitor 1 (ERRFI1), a crucial negative regulator of EGFR, thereby causing EGFR feedback activation. Notably, wild-type isoforms of RAS, including H-RAS and N-RAS, but not oncogenic K-RAS, mediated signaling downstream of activated EGFR, leading to RAS effector signaling rebound and reduced MRTX1133 efficacy. Blockade of activated EGFR with clinically used antibodies or kinase inhibitors suppressed the EGFR/wild-type RAS signaling axis, sensitized MRTX1133 monotherapy, and caused the regression of KRAS G12D -mutant CRC organoids and cell line-derived xenografts. Overall, this study uncovers feedback activation of EGFR as a prominent molecular event that restricts KRAS G12D inhibitor efficacy and establishes a potential combination therapy consisting of KRAS G12D and EGFR inhibitors for patients with KRAS G12D -mutated CRC.

Overview

CoChat Summary

TL;DR

MRTX1133 causes reversible growth arrest in KRASG12D-mutated colorectal cancer cells and feedback activation of EGFR/wild-type RAS signaling, limiting its efficacy. Combining MRTX1133 with EGFR inhibitors is synthetic lethal and produces tumor regression in CRC models.

Key findings

  • MRTX1133 selectively impaired KRASG12D-mutant cancer cells, including LS180, LS174T, and LS513, with IC50 values of 5–40 nM, whereas non-KRASG12D-mutant cells had IC50 >10 μM; treatment caused G2/M arrest and reversible growth arrest after washout.
  • A kinome CRISPR-Cas9 screen (5960 sgRNAs targeting 503 human kinases) identified EGFR as the top-ranked synthetic lethal candidate with MRTX1133; EGFR knockdown or EGFR inhibitors cetuximab/gefitinib synergized with MRTX1133, with CI values <0.7 at ED50, ED75, and ED90 and ZIP synergy scores of 15–30.
  • Mechanistically, MRTX1133 downregulated ERRFI1, causing EGFR feedback activation; activated EGFR signaled through wild-type H-RAS and N-RAS, but not oncogenic K-RAS, leading to p-ERK/p-AKT rebound. EGFR blockade suppressed wild-type RAS-GTP and the RAS effector rebound.
  • In LS180 and LS174T xenografts (n = 7 per group; MRTX1133 20 mg/kg, cetuximab 50 mg/kg), combination treatment inhibited tumor growth, prolonged survival, reduced Ki67, and decreased ERRFI1/p-ERK/p-AKT; KRASG12D-mutant patient-derived organoids T38 and T39 also responded more potently to combination treatment.

Methods

  • In vitro assays used KRASG12D-mutant and non-mutant CRC cell lines, patient-derived organoids (T38, T39), cell viability, colony formation, cell-cycle analysis, western blot, RT-qPCR, RAS-GTP pulldown, and immunohistochemistry.
  • A CRISPR-Cas9 kinome loss-of-function screen was performed in LS174T cells treated with or without 25 nM MRTX1133, followed by a chemical mini-screen with EGFR, MEK, mTOR, PI3K, SHP2, and CDK4/6 inhibitors; synergy was assessed by CI and ZIP scores.
  • In vivo studies used subcutaneous LS180 and LS174T xenografts in nude mice treated for 21 days with vehicle, MRTX1133, cetuximab, or combination; tumor volume and survival were measured, with two-tailed t-tests, one-way ANOVA with Tukey’s test, and log-rank tests.

Limitations

  • The paper does not state limitations.
  • Evident: the study relies on two KRASG12D-mutant CRC cell lines and two patient-derived organoid models, so broader CRC heterogeneity and other KRASG12D CRC contexts are not fully captured.
  • Evident: in vivo efficacy was tested in immunodeficient xenograft models, not patient tumors; survival analysis used tumor-volume thresholds (1000 mm3 for death surrogate; 1500 mm3 for euthanasia), and no clinical trial data are reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41388-023-02676-9

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 MRTX1133 provokes RAS effector signaling rebound in CRC cells. A Cellular activity of MRTX1133 across a panel of KRASG12D and non-KRASG12D mutant cell lines measured as the effects on 2D cell viability after a 5 days treatment. First data points of the curves represent the untreated control. Data are represented as mean ± SEM of three independent experiments with five technical replicates each. B Effects of MRTX1133 on cell-cycle of LS180 and LS174T cells. Cells were treated with MRTX1133 for 72 h and stained with PI to analyze the cell cycle distribution by flow cytometry. Values are expressed as the mean ± SEM of three replicates. ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. C Representative images (left) and relative numbers (right) of LS180 and LS174T cells treated with concentration gradients of MRTX1133 for 10 days, or various concentrations of MRTX1133 for 5 days followed by a switch to fresh medium (washout) for 5 days. Data represent the mean ± SEM of five replicates. ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. D Pathway enrichment was determined by GSEA from the RNA-seq dataset (Jill Hallin et al. GSE201412). LS180 cells were treated with 100 nM MRTX1133 for 3 and 24 h and then profiled by RNA sequencing (n = 3). NES, normalized enrichment score; NOM P-val, nominal P-value; FDR q-val, false discovery rate q-value. E Heatmap depicting differential expression of MAPK or AKT pathway-associated gene sets from the public RNA-seq dataset (Jill Hallin et al. GSE201412). Z-score was calculated based on counts of exon model per million mapped reads. F Western immunoblot analysis of ERK or AKT activation upon treatment with MRTX1133 for 3 and 24 h. GAPDH is used as loading control.
Fig. 1 MRTX1133 provokes RAS effector signaling rebound in CRC cells. A Cellular activity of MRTX1133 across a panel of KRASG12D and non-KRASG12D mutant cell lines measured as the effects on 2D cell viability after a 5 days treatment. First data points of the curves represent the untreated control. Data are represented as mean ± SEM of three independent experiments with five technical replicates each. B Effects of MRTX1133 on cell-cycle of LS180 and LS174T cells. Cells were treated with MRTX1133 for 72 h and stained with PI to analyze the cell cycle distribution by flow cytometry. Values are expressed as the mean ± SEM of three replicates. ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. C Representative images (left) and relative numbers (right) of LS180 and LS174T cells treated with concentration gradients of MRTX1133 for 10 days, or various concentrations of MRTX1133 for 5 days followed by a switch to fresh medium (washout) for 5 days. Data represent the mean ± SEM of five replicates. ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. D Pathway enrichment was determined by GSEA from the RNA-seq dataset (Jill Hallin et al. GSE201412). LS180 cells were treated with 100 nM MRTX1133 for 3 and 24 h and then profiled by RNA sequencing (n = 3). NES, normalized enrichment score; NOM P-val, nominal P-value; FDR q-val, false discovery rate q-value. E Heatmap depicting differential expression of MAPK or AKT pathway-associated gene sets from the public RNA-seq dataset (Jill Hallin et al. GSE201412). Z-score was calculated based on counts of exon model per million mapped reads. F Western immunoblot analysis of ERK or AKT activation upon treatment with MRTX1133 for 3 and 24 h. GAPDH is used as loading control.CC BY · PubMed Central
Fig. 2 Identification of EGFR as a synthetic lethal target of MRTX1133. A Schematic outline of the viability-based, human kinome CRISPR-Cas9 loss-of-function screen. B Gene scores in untreated control versus MRTX1133-treated (25 nM) LS174T cells. The gene score was the median log2 fold change in the abundance of all sgRNAs targeting that gene during the culture period. Most genes, as well as non-targeting control sgRNAs, have similar scores in the presence or absence of MRTX1133. C Knockdown of EGFR enhance the response to MRTX1133 in LS180 and LS174T cells. Top, EGFR knockdown efficiency of the shRNAs was measured by immunoblot analysis. Bottom, Relative viability of the cultured colonies. Data are shown as mean ± SEM of five replicates. ***P < 0.001, by unpaired, two-sided Student’s t-test. D Synergistic interaction between MRTX1133 and EGFRi (cetuximab and gefitinib), MEKi (trametinib), mTORi (rapamycin), PI3Ki (alpelisib), SHP2i (RMC-4550), or CDK4/6i (albociclib) in LS174T cells. CI values at ED50, ED75, and ED90 were calculated using CalcuSyn software. CI values of less than 0.7 represent strongly synergism.
Fig. 2 Identification of EGFR as a synthetic lethal target of MRTX1133. A Schematic outline of the viability-based, human kinome CRISPR-Cas9 loss-of-function screen. B Gene scores in untreated control versus MRTX1133-treated (25 nM) LS174T cells. The gene score was the median log2 fold change in the abundance of all sgRNAs targeting that gene during the culture period. Most genes, as well as non-targeting control sgRNAs, have similar scores in the presence or absence of MRTX1133. C Knockdown of EGFR enhance the response to MRTX1133 in LS180 and LS174T cells. Top, EGFR knockdown efficiency of the shRNAs was measured by immunoblot analysis. Bottom, Relative viability of the cultured colonies. Data are shown as mean ± SEM of five replicates. ***P < 0.001, by unpaired, two-sided Student’s t-test. D Synergistic interaction between MRTX1133 and EGFRi (cetuximab and gefitinib), MEKi (trametinib), mTORi (rapamycin), PI3Ki (alpelisib), SHP2i (RMC-4550), or CDK4/6i (albociclib) in LS174T cells. CI values at ED50, ED75, and ED90 were calculated using CalcuSyn software. CI values of less than 0.7 represent strongly synergism.CC BY · PubMed Central
Fig. 3 ERRFI1 downregulation by MRTX1133 causes EGFR adaptive reactivation. A Effects of MRTX1133 on the p-EGFR expression in KRASG12D-mutant CRC cells. LS180, LS174T, and LS513 cells were treated with indicated concentration of MRTX1133 for 3 or 24 h. Cell lysates were probed with antibodies against p-EGFR, EGFR and GAPDH. B Immunohistochemical analysis of p-EGFR in LS174T xenograft tumors. Tumors were isolated after 3 or 7-day administration of MRTX1133. Immunohistochemical staining assay were detected (left). Scale bars, 200 μm. Percent of tumor cell positive for p-EGFR assessed (right). Data represent the mean ± SEM. **P < 0.01, ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. C Cell viability assay. LS180 and LS174T cells were treated with EGF (20 ng/mL) and/or cetuximab (50 μg/mL), or with untreated control, and detected their sensitivity to MRTX1133. Each point on the dose-response curves represents five technical replicates. Data are shown as mean ± SEM. The charts below show the IC50 values. D Western immunoblot analysis of LS180 and LS174T cells treated with EGF (20 ng/mL), cetuximab (50 μg/mL), and/or MRTX1133 (30 nM) as indicated for 30 min. E RNA-seq analysis of EGFR negative regulators (ERRFI1, CDC25C, and CBL) in vitro and in vivo (Jill Hallin et al. GSE201412). F, G MRTX1133 downregulated ERRFI1 expression at the transcription (F) and protein levels (G) in a concentration- or time-dependent manner. LS180 and LS174T cells were treated with MRTX1133 for the indicated durations. ERRFI1 expression was detected by western immunoblot and RT-qPCR assays. Data are presented as mean ± SEM of three technical replicates. **P < 0.01, and ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. H ERFFI1 silencing impaired the inhibitory effects of MRTX1133 on LS180 and LS174T cells. Left, ERRFI1 knockdown efficiency in LS180 and LS174T cells by immunoblot analysis. Right, colony formation assay. Data represent the mean ± SEM of biological triplicates. ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test.
Fig. 3 ERRFI1 downregulation by MRTX1133 causes EGFR adaptive reactivation. A Effects of MRTX1133 on the p-EGFR expression in KRASG12D-mutant CRC cells. LS180, LS174T, and LS513 cells were treated with indicated concentration of MRTX1133 for 3 or 24 h. Cell lysates were probed with antibodies against p-EGFR, EGFR and GAPDH. B Immunohistochemical analysis of p-EGFR in LS174T xenograft tumors. Tumors were isolated after 3 or 7-day administration of MRTX1133. Immunohistochemical staining assay were detected (left). Scale bars, 200 μm. Percent of tumor cell positive for p-EGFR assessed (right). Data represent the mean ± SEM. **P < 0.01, ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. C Cell viability assay. LS180 and LS174T cells were treated with EGF (20 ng/mL) and/or cetuximab (50 μg/mL), or with untreated control, and detected their sensitivity to MRTX1133. Each point on the dose-response curves represents five technical replicates. Data are shown as mean ± SEM. The charts below show the IC50 values. D Western immunoblot analysis of LS180 and LS174T cells treated with EGF (20 ng/mL), cetuximab (50 μg/mL), and/or MRTX1133 (30 nM) as indicated for 30 min. E RNA-seq analysis of EGFR negative regulators (ERRFI1, CDC25C, and CBL) in vitro and in vivo (Jill Hallin et al. GSE201412). F, G MRTX1133 downregulated ERRFI1 expression at the transcription (F) and protein levels (G) in a concentration- or time-dependent manner. LS180 and LS174T cells were treated with MRTX1133 for the indicated durations. ERRFI1 expression was detected by western immunoblot and RT-qPCR assays. Data are presented as mean ± SEM of three technical replicates. **P < 0.01, and ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. H ERFFI1 silencing impaired the inhibitory effects of MRTX1133 on LS180 and LS174T cells. Left, ERRFI1 knockdown efficiency in LS180 and LS174T cells by immunoblot analysis. Right, colony formation assay. Data represent the mean ± SEM of biological triplicates. ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test.CC BY · PubMed Central
Fig. 4 Wild-type RAS drives RAS effector signaling rebound. A MRTX1133 increased wild-type RAS-GTP levels. LS180 and LS174T cells were treated with MRTX1133 for 24 h and lysates were subjected to GST-RAF-RBD pulldown assay. Immunoblot analysis was subsequently performed. The relative density of K-RAS-, H-RAS-, and N-RAS-GTP bands versus their respective RAS inputs is shown. B ERRFI1 silencing increased wild-type RAS-GTP levels. Lysates of LS180 cells after ERRFI1 silencing were subjected to GST-RAF-RBD pulldown assay. The relative density of RAS-GTP bands versus their respective RAS inputs was quantified. C Wild-type RAS knockdown impaired MRTX1133-mediated RAS signaling activation. LS180 cells were subject to siRNA knockdown of H-RAS, N-RAS, or both wild-type RAS and treated with or without MRTX1133 for 24 h. Immunoblot analysis was performed for p-ERK and p-AKT. D Wild-type RAS silencing potentiated MRTX1133 efficacy in LS180 cells. Cells were subject to siRNA knockdown of H-RAS, N-RAS, or both wild-type RAS and treated with 30 nM MRTX1133 for 7 days. Data are presented as mean ± SEM of three technical replicates. ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. E Increased wild-type RAS-GTP levels require EGFR activation. LS180 cells were treated with 30 nM MRTX1133, 50 μg/mL cetuximab or their combination for 24 h. H-RAS and N-RAS were detected by western immunoblot assay. The relative density of GTP-bound forms of RAS proteins is shown. F A proposed model for the regulation of EGFR/wild-type RAS signaling by MRTX1133.
Fig. 4 Wild-type RAS drives RAS effector signaling rebound. A MRTX1133 increased wild-type RAS-GTP levels. LS180 and LS174T cells were treated with MRTX1133 for 24 h and lysates were subjected to GST-RAF-RBD pulldown assay. Immunoblot analysis was subsequently performed. The relative density of K-RAS-, H-RAS-, and N-RAS-GTP bands versus their respective RAS inputs is shown. B ERRFI1 silencing increased wild-type RAS-GTP levels. Lysates of LS180 cells after ERRFI1 silencing were subjected to GST-RAF-RBD pulldown assay. The relative density of RAS-GTP bands versus their respective RAS inputs was quantified. C Wild-type RAS knockdown impaired MRTX1133-mediated RAS signaling activation. LS180 cells were subject to siRNA knockdown of H-RAS, N-RAS, or both wild-type RAS and treated with or without MRTX1133 for 24 h. Immunoblot analysis was performed for p-ERK and p-AKT. D Wild-type RAS silencing potentiated MRTX1133 efficacy in LS180 cells. Cells were subject to siRNA knockdown of H-RAS, N-RAS, or both wild-type RAS and treated with 30 nM MRTX1133 for 7 days. Data are presented as mean ± SEM of three technical replicates. ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. E Increased wild-type RAS-GTP levels require EGFR activation. LS180 cells were treated with 30 nM MRTX1133, 50 μg/mL cetuximab or their combination for 24 h. H-RAS and N-RAS were detected by western immunoblot assay. The relative density of GTP-bound forms of RAS proteins is shown. F A proposed model for the regulation of EGFR/wild-type RAS signaling by MRTX1133.CC BY · PubMed Central
Fig. 5 Targeted inhibition of EGFR synergizes with MRTX1133 in vitro. A EGFR inhibition enhanced the efficacy of MRTX1133 in KRASG12D-mutant CRC cell lines. LS180, LS174T and LS513 cells were treated with concentration gradients of MRTX1133 with or without cetuximab (50 μg/mL), panitinib (50 μg/mL), or gefitinib (150 nM) for 5 days. Shown are cell viability curves. Data represent the mean ± SEM of biological triplicates. B Synergy diagram of MRTX1133 and cetuximab (top), MRTX1133 and gefitinib (bottom) analyzed by R package “synergyfinder”. LS180 and LS174T cells were treated for 72 h with various concentrations of the indicated inhibitors. The concentrations of EGFRi or MRTX1133 were used in a two-fold dilution series (3.13, 6.25, 12.5, 25, 50, and 100 μg/mL for cetuximab; 31.3, 62.5, 125, 250, 500, and 1000 nM for gefitinib; 6.25, 12.5, 25, 50, 100, and 200 nM for MRTX1133). Relative cell viability was subsequently measured. ZIP values were simulated using zero interaction potency model analysis. C Inhibition of clonogenic viability by the combined regimen. LS180 and LS174T cells were treated with MRTX1133, EGFRi (cetuximab and gefitinib), or their combination as indicated. Quantified clonogenic viability inhibition results are shown. Data are mean ± SEM of five technical replicates. D LS180 and LS174T cells treated with the indicated MRTX1133, EGFRi (cetuximab and gefitinib), or their combination for 3 or 24 h were assessed by western immunoblot. E Cell-cycle profiles. Data represent the mean ± SEM of biological triplicates. ***P < 0.001; ns, no significant, by one-way ANOVA with Tukey’s multiple-comparisons test. F Immunoblot analysis of cleaved PARP in LS180 and LS174T cells. Cells were treated with MRTX1133, EGFRi (cetuximab and gefitinib), or their combination for 72 h. Cell lysates were probed with antibodies against cleaved PARP and GAPDH.
Fig. 5 Targeted inhibition of EGFR synergizes with MRTX1133 in vitro. A EGFR inhibition enhanced the efficacy of MRTX1133 in KRASG12D-mutant CRC cell lines. LS180, LS174T and LS513 cells were treated with concentration gradients of MRTX1133 with or without cetuximab (50 μg/mL), panitinib (50 μg/mL), or gefitinib (150 nM) for 5 days. Shown are cell viability curves. Data represent the mean ± SEM of biological triplicates. B Synergy diagram of MRTX1133 and cetuximab (top), MRTX1133 and gefitinib (bottom) analyzed by R package “synergyfinder”. LS180 and LS174T cells were treated for 72 h with various concentrations of the indicated inhibitors. The concentrations of EGFRi or MRTX1133 were used in a two-fold dilution series (3.13, 6.25, 12.5, 25, 50, and 100 μg/mL for cetuximab; 31.3, 62.5, 125, 250, 500, and 1000 nM for gefitinib; 6.25, 12.5, 25, 50, 100, and 200 nM for MRTX1133). Relative cell viability was subsequently measured. ZIP values were simulated using zero interaction potency model analysis. C Inhibition of clonogenic viability by the combined regimen. LS180 and LS174T cells were treated with MRTX1133, EGFRi (cetuximab and gefitinib), or their combination as indicated. Quantified clonogenic viability inhibition results are shown. Data are mean ± SEM of five technical replicates. D LS180 and LS174T cells treated with the indicated MRTX1133, EGFRi (cetuximab and gefitinib), or their combination for 3 or 24 h were assessed by western immunoblot. E Cell-cycle profiles. Data represent the mean ± SEM of biological triplicates. ***P < 0.001; ns, no significant, by one-way ANOVA with Tukey’s multiple-comparisons test. F Immunoblot analysis of cleaved PARP in LS180 and LS174T cells. Cells were treated with MRTX1133, EGFRi (cetuximab and gefitinib), or their combination for 72 h. Cell lysates were probed with antibodies against cleaved PARP and GAPDH.CC BY · PubMed Central
Fig. 6 Co-treatment of MRTX1133 and EGFR inhibitors impedes CRC organoid growth. A, B Inhibition of organoids proliferation by the combined regimen. T38 (A) and T39 (B) PDOs were treated with various concentrations of the indicated inhibitors. Top, Representative bright-field microscopy images of organoids. Bottom, Quantification of organoid size change curves after drug combinations. Data represent the mean ± SEM. **P < 0.01, and ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. C T38 PDO were treated with MRTX1133 and EGFRi for 24 h, and western immunoblot analysis was performed with the indicated antibodies. GAPDH served as a loading control.
Fig. 6 Co-treatment of MRTX1133 and EGFR inhibitors impedes CRC organoid growth. A, B Inhibition of organoids proliferation by the combined regimen. T38 (A) and T39 (B) PDOs were treated with various concentrations of the indicated inhibitors. Top, Representative bright-field microscopy images of organoids. Bottom, Quantification of organoid size change curves after drug combinations. Data represent the mean ± SEM. **P < 0.01, and ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. C T38 PDO were treated with MRTX1133 and EGFRi for 24 h, and western immunoblot analysis was performed with the indicated antibodies. GAPDH served as a loading control.CC BY · PubMed Central
Fig. 7 EGFR inhibition sensitizes KRASG12D-mutant CRC to MRTX1133 in vivo. A Growth curves of LS180 xenografts in mice (n = 7 per group). Athymic nude mice bearing LS180 xenografts were treated with vehicle, MRTX1133 (20 mg/kg, intraperitoneally once a day), cetuximab (50 mg/kg, intraperitoneally twice a week), or combination for 21 days. Tumor volumes were measured every three days. Data represent the mean ± SEM. ***P < 0.001, by unpaired, two-sided Student’s t-test. B Kaplan-Meier survival curves of LS180 xenografts after the indicated treatment (n = 7 per group). *P < 0.05, and ***P < 0.001, by log-rank tests. C Growth curves of LS174T xenografts in mice (n = 7 per group). Athymic nude mice bearing LS174T xenografts were treated as in (A). Data represent the mean ± SEM. ***P < 0.001, by unpaired, two-sided Student’s t-test. D Kaplan-Meier survival curves of LS174T xenografts (n = 7 per group). ***P < 0.001; ns, not significant, by log-rank tests. E Immunohistochemical staining for Ki-67 from LS174T xenografts tumors. Representative images of immunohistochemical staining for Ki-67 in tumor samples after 21-day treatment (left). Scale bars, 200 μm. Percent of tumor cell positive for Ki-67 assessed (right). Data represent the mean ± SEM. **P < 0.01, and ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. F RT-qPCR analysis of ERRFI1 in LS174T xenograft tumors. At the end of the treatment, LS174T xenograft tumors were isolated from mice. RT-qPCR assay were detected. Data represent the mean ± SEM of six independent biologically samples. *P < 0.05, and *** P < 0.001; ns, no significant, by one-way ANOVA with Tukey’s multiple-comparisons test. G Immunoblot analysis of p-ERK, p-AKT, and ERRFI1 in LS174T xenograft tumors. Three biologically independent samples per group are shown.
Fig. 7 EGFR inhibition sensitizes KRASG12D-mutant CRC to MRTX1133 in vivo. A Growth curves of LS180 xenografts in mice (n = 7 per group). Athymic nude mice bearing LS180 xenografts were treated with vehicle, MRTX1133 (20 mg/kg, intraperitoneally once a day), cetuximab (50 mg/kg, intraperitoneally twice a week), or combination for 21 days. Tumor volumes were measured every three days. Data represent the mean ± SEM. ***P < 0.001, by unpaired, two-sided Student’s t-test. B Kaplan-Meier survival curves of LS180 xenografts after the indicated treatment (n = 7 per group). *P < 0.05, and ***P < 0.001, by log-rank tests. C Growth curves of LS174T xenografts in mice (n = 7 per group). Athymic nude mice bearing LS174T xenografts were treated as in (A). Data represent the mean ± SEM. ***P < 0.001, by unpaired, two-sided Student’s t-test. D Kaplan-Meier survival curves of LS174T xenografts (n = 7 per group). ***P < 0.001; ns, not significant, by log-rank tests. E Immunohistochemical staining for Ki-67 from LS174T xenografts tumors. Representative images of immunohistochemical staining for Ki-67 in tumor samples after 21-day treatment (left). Scale bars, 200 μm. Percent of tumor cell positive for Ki-67 assessed (right). Data represent the mean ± SEM. **P < 0.01, and ***P < 0.001, by one-way ANOVA with Tukey’s multiple-comparisons test. F RT-qPCR analysis of ERRFI1 in LS174T xenograft tumors. At the end of the treatment, LS174T xenograft tumors were isolated from mice. RT-qPCR assay were detected. Data represent the mean ± SEM of six independent biologically samples. *P < 0.05, and *** P < 0.001; ns, no significant, by one-way ANOVA with Tukey’s multiple-comparisons test. G Immunoblot analysis of p-ERK, p-AKT, and ERRFI1 in LS174T xenograft tumors. Three biologically independent samples per group are shown.CC BY · PubMed Central

Verification

Claims the paper makes

17 Valid · 2 Not valid · 4 Not checked · 72 Own results and interpretations

51 more claims

Create a free account to see all 95 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 18
  • It may state two separate claims as one. 25

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 54 references

Cited by

See all 95

Metadata

Authors
Feng, J., Hu, Z., Xia, X., Liu, X., Lian, Z., Wang, H., Wang, L., Wang, C., Zhang, X., & Pang, X.
Affiliations
  • Southern Medical University (CN)
  • East China Normal University (CN)
  • Shanghai Jiao Tong University (CN)
Corresponding author
  • Zhang, Xueli
  • Pang, Xiufeng
Venue
Oncogene
Published
2023-04-05
Volume
42
Issue
20
Pages
1620-1633
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W4362638696
Cited by
95
References
61
Citations by year
2026: 35 · 2025: 32 · 2024: 20 · 2023: 8
FWCI
8.43
Type
journal article
Language
en
Open access
Licence
Locations
  • Oncogene (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (82122045, 82073073, 81874207)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS G12D, colorectal cancer, EGFR, Ras signaling, MRTX1133, KRAS inhibitor resistance, synthetic lethality, ERRFI1, H-Ras, NRAS, EGFR inhibitors, combination therapy, colorectal cancer organoids
MeSH terms
Heterocyclic Compounds, 2-Ring, Humans, Mutation, Naphthalenes, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Feedback, Physiological, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer. https://app.cochat.ai/papers/10.1038/s41388-023-02676-9
The paper
Feng, J., Hu, Z., Xia, X., Liu, X., Lian, Z., Wang, H., Wang, L., Wang, C., Zhang, X., & Pang, X. (2023). Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer. Oncogene. https://doi.org/10.1038/s41388-023-02676-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.